These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 14560009

  • 1. Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses.
    Droin NM, Pinkoski MJ, Dejardin E, Green DR.
    Mol Cell Biol; 2003 Nov; 23(21):7638-47. PubMed ID: 14560009
    [Abstract] [Full Text] [Related]

  • 2. Nonlymphoid Fas ligand in peptide-induced peripheral lymphocyte deletion.
    Pinkoski MJ, Droin NM, Lin T, Genestier L, Ferguson TA, Green DR.
    Proc Natl Acad Sci U S A; 2002 Dec 10; 99(25):16174-9. PubMed ID: 12454289
    [Abstract] [Full Text] [Related]

  • 3. Role of Egr-2 in up-regulation of Fas ligand in normal T cells and aberrant double-negative lpr and gld T cells.
    Mittelstadt PR, Ashwell JD.
    J Biol Chem; 1999 Jan 29; 274(5):3222-7. PubMed ID: 9915863
    [Abstract] [Full Text] [Related]

  • 4. Cyclosporin A-sensitive transcription factor Egr-3 regulates Fas ligand expression.
    Mittelstadt PR, Ashwell JD.
    Mol Cell Biol; 1998 Jul 29; 18(7):3744-51. PubMed ID: 9632757
    [Abstract] [Full Text] [Related]

  • 5. Hepatitis B virus X protein induces expression of Fas ligand gene through enhancing transcriptional activity of early growth response factor.
    Yoo YG, Lee MO.
    J Biol Chem; 2004 Aug 27; 279(35):36242-9. PubMed ID: 15173177
    [Abstract] [Full Text] [Related]

  • 6. Tumor necrosis factor alpha up-regulates non-lymphoid Fas-ligand following superantigen-induced peripheral lymphocyte activation.
    Pinkoski MJ, Droin NM, Green DR.
    J Biol Chem; 2002 Nov 01; 277(44):42380-5. PubMed ID: 12196549
    [Abstract] [Full Text] [Related]

  • 7. Effect of H. pylori on the expression of TRAIL, FasL and their receptor subtypes in human gastric epithelial cells and their role in apoptosis.
    Martin JH, Potthoff A, Ledig S, Cornberg M, Jandl O, Manns MP, Kubicka S, Flemming P, Athmann C, Beil W, Wagner S.
    Helicobacter; 2004 Oct 01; 9(5):371-86. PubMed ID: 15361075
    [Abstract] [Full Text] [Related]

  • 8. Chronic morphine treatment promotes specific Th2 cytokine production by murine T cells in vitro via a Fas/Fas ligand-dependent mechanism.
    Greeneltch KM, Kelly-Welch AE, Shi Y, Keegan AD.
    J Immunol; 2005 Oct 15; 175(8):4999-5005. PubMed ID: 16210602
    [Abstract] [Full Text] [Related]

  • 9. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
    Delgado M, Ganea D.
    J Immunol; 2001 Jan 15; 166(2):1028-40. PubMed ID: 11145682
    [Abstract] [Full Text] [Related]

  • 10. Defining the roles of perforin, Fas/FasL, and tumour necrosis factor alpha in T cell induced mucosal damage in the mouse intestine.
    Merger M, Viney JL, Borojevic R, Steele-Norwood D, Zhou P, Clark DA, Riddell R, Maric R, Podack ER, Croitoru K.
    Gut; 2002 Aug 15; 51(2):155-63. PubMed ID: 12117872
    [Abstract] [Full Text] [Related]

  • 11. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines.
    Shetty S, Gladden JB, Henson ES, Hu X, Villanueva J, Haney N, Gibson SB.
    Apoptosis; 2002 Oct 15; 7(5):413-20. PubMed ID: 12207174
    [Abstract] [Full Text] [Related]

  • 12. Antigen-primed CD8+ T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1-, and TRAIL-dependent killing.
    Komatsu M, Mammolenti M, Jones M, Jurecic R, Sayers TJ, Levy RB.
    Blood; 2003 May 15; 101(10):3991-9. PubMed ID: 12521999
    [Abstract] [Full Text] [Related]

  • 13. Synthetic peptides corresponding to ligand-binding region of death receptors, DR5, Fas, and TNFR, specifically inhibit cell death mediated by the death ligands, respectively.
    Kajiwara K, Saito A, Ogata S, Tanihara M.
    Biochim Biophys Acta; 2004 Jun 01; 1699(1-2):131-7. PubMed ID: 15158720
    [Abstract] [Full Text] [Related]

  • 14. Mechanism of chronic obstructive uropathy: increased expression of apoptosis-promoting molecules.
    Choi YJ, Baranowska-Daca E, Nguyen V, Koji T, Ballantyne CM, Sheikh-Hamad D, Suki WN, Truong LD.
    Kidney Int; 2000 Oct 01; 58(4):1481-91. PubMed ID: 11012883
    [Abstract] [Full Text] [Related]

  • 15. FasL promoter activation by IL-2 through SP1 and NFAT but not Egr-2 and Egr-3.
    Xiao S, Matsui K, Fine A, Zhu B, Marshak-Rothstein A, Widom RL, Ju ST.
    Eur J Immunol; 1999 Nov 01; 29(11):3456-65. PubMed ID: 10556800
    [Abstract] [Full Text] [Related]

  • 16. Modulation of death receptor pathways in oncology.
    de Vries EG, Timmer T, Mulder NH, van Geelen CM, van der Graaf WT, Spierings DC, de Hooge MN, Gietema JA, de Jong S.
    Drugs Today (Barc); 2003 Nov 01; 39 Suppl C():95-109. PubMed ID: 14988748
    [Abstract] [Full Text] [Related]

  • 17. Differential expression of Fas ligand in Th1 and Th2 cells is regulated by early growth response gene and NF-AT family members.
    Dzialo-Hatton R, Milbrandt J, Hockett RD, Weaver CT.
    J Immunol; 2001 Apr 01; 166(7):4534-42. PubMed ID: 11254710
    [Abstract] [Full Text] [Related]

  • 18. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study.
    Reesink-Peters N, Hougardy BM, van den Heuvel FA, Ten Hoor KA, Hollema H, Boezen HM, de Vries EG, de Jong S, van der Zee AG.
    Gynecol Oncol; 2005 Mar 01; 96(3):705-13. PubMed ID: 15721415
    [Abstract] [Full Text] [Related]

  • 19. Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice.
    Ishikawa E, Nakazawa M, Yoshinari M, Minami M.
    J Virol; 2005 Jun 01; 79(12):7658-63. PubMed ID: 15919918
    [Abstract] [Full Text] [Related]

  • 20. TRAIL-induced cell death cooperates with IFN-gamma activation in the graft-versus-tumor effect against colon tumors.
    Tateishi K, Ohta M, Guleng B, Kanai F, Tanaka Y, Asaoka Y, Jazag A, Imamura J, Imamura T, Ijichi H, Ikenoue T, Kawakami T, Fukushima Y, Washida M, Sata M, Miyagishi M, Taira K, Yoshida H, Kawabe T, Omata M.
    Int J Cancer; 2006 May 01; 118(9):2237-46. PubMed ID: 16331624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.